A Phase-1, Parallel-Design, Open-Label, Randomized, Multiple-Dose Escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of LY3549492 in Healthy Participants With Overweight or Obesity
Eli Lilly and Company
Summary
The purpose of this study is to see how safe and well-tolerated the drug LY3549492 is and how it behaves in the body, when given in multiple doses to healthy people who are overweight or have obesity. Participation in the study will last approximately 8 weeks.
Eligibility
- Age range
- 18–65 years
- Sex
- All
- Healthy volunteers
- Yes
Inclusion Criteria: * Have a hemoglobin A1c level of less than 6.5 percent (%) at screening. * Have a body mass index (BMI) of 25.0 to 45.0 kilogram per square meter (kg/m²), inclusive, at screening * Participants assigned male at birth (AMAB) or participants assigned female at birth (AFAB) who are individual of childbearing potential (INOCBP) Contraceptive use by participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Exclusion Criteria: * Have obesity induced by endocrine disorders such as Cushing's syndr…
Interventions
- DrugLY3549492
Administered orally
Locations (3)
- Fortrea Clinical Research UnitDaytona Beach, Florida
- Fortrea Clinical Research UnitDallas, Texas
- Fortrea Clinical Research UnitMadison, Wisconsin